NCT02402062已完成2 期
A Phase II Study to Assess the Activity and Safety of TH-302 in Combination With Sunitinib in Treatment-naïve Patients With Well- and Moderately-differentiated Metastatic Pancreatic Neuroendocrine Tumours (pNET)
Grupo Espanol de Tumores Neuroendocrinos10 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2015年5月11日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 17
- 试验地点
- 10
- 主要终点
- Objective Response Rate
研究概览
简要总结
The purpose of this study is to determine the safety and the efficacy of the combination of the drugs TH-302 and sunitinib in metastatic neuroendocrine tumours.
详细描述
The purpose of this study is to determine the safety and the efficacy of the combination of the drugs TH-302 and sunitinib in Treatment-naïve patients with well- and moderately-differentiated metastatic Pancreatic Neuroendocrine Tumours (pNET).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, 18 years of age or older.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-
- •Histologically proven diagnosis of pancreatic neuroendocrine tumors (pNET) with Ki67 assessment of ≤ 20% (well and moderately differentiated)
- •Evidence of unresectable disease or metastatic disease. Locally advanced disease must not be amendable to resection or radiation therapy with curative intent.
- •Patients may be treated with somatostatin analogues prior or during the trial. Concomitant or prior interferon treatment is not permitted.
- •Documented progression disease by CT scan, magnetic resonance (MR) or Octreoscan in 12 months prior basal visit.
- •Measurable disease as per RECIST. Measurable lesions that have been previously radiated will not be considered target lesions unless increase in size has been observed following completion of radiation therapy.
- •Patient has to be able to swallow the medication.
- •Life expectancy greater than 12 weeks.
- •The definitions of minimum adequacy for organ function required prior to study entry are as follows:
- •Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 2.5 x upper limit of normal (ULN), or AST and ALT ≤ 5 x ULN if liver function abnormalities are due to underlying malignancy
- •Total serum bilirubin ≤ 1.5 x ULN
- •Serum albumin ≥ 3.0 g/dL
- •Absolute neutrophil count (ANC) ≥ 1500/µL
- •Platelets ≥ 100,000/µL
- •Hemoglobin ≥ 5,6 mmol/L (9.0 g/dL)
- •Creatinin clearance > 40 mL/min (Cockcroft and Gault formula)
- •Adequate cardiac function: 12-lead ECG without pathologic findings (clinically significant alterations are allowed) and Echocardiogram / Normal multiple gated acquisition scan (MUGA) (LVEF> 50%)
- •Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment.
- •Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
排除标准
- •Previous treatments with chemotherapy, monoclonal antibodies anti-vascular endothelial growth factor (VEGF), tyrosine kinase inhibitors, mammalian target of rapamycin (mTOR) inhibitors, or interferon are not permitted for the advanced disease.
- •Prior treatment on another hypoxia-activated prodrug under clinical trial.
- •Major surgery, radiation therapy, or systemic therapy within 3 weeks of study randomization except palliative radiotherapy to non-target metastatic lesions.
- •Prior high-dose chemotherapy requiring hematopoietic stem cell rescue.
- •Immunosuppressive drugs such as cyclosporine, tacrolimus, azathioprine, or long-term oral glucocorticoids taken concurrently or within last 3 months prior to randomization
- •Treatment with known inhibitors or inductors of cytochrome P450 3A4 (CYP3A4) or that prolong the QT interval in the previous 7 days.
- •Prior radiation therapy to > 25% of the bone marrow.
- •Current treatment on another clinical trial.
- •Uncontrolled brain metastases, spinal cord compression, carcinomatous meningitis, or leptomeningeal disease. Patients should have completed surgery or radiation therapy for existing brain metastases, should not have documented increase in size over the previous 3 months prior to first dose of treatment on study and should be asymptomatic.
- •Diagnosis of any second malignancy within the last 3 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.
- •Any of the following within the 12 months prior to starting study treatment:
- •myocardial infarction,
- •severe/unstable angina,
- •coronary/peripheral artery bypass graft,
- •congestive heart failure class III or IV of the New York Heart Association (NYHA) or patients with clinical history of congestive heart failure class III or IV of the NYHA, unless an echocardiogram or MUGA in the previous 3 months to selection shows a LVEF ? 45 %
- •significant heart valve disease
- •cerebrovascular accident including transient ischemic attack
- •pulmonary embolus.
- •Ongoing cardiac dysrhythmias of NCI Common Toxicity Criteria for Adverse Effects (CTCAE) grade ≥ 2, atrial fibrillation of any grade, or corrected QT interval (QTc) interval >450 msec for males or >470 msec for females.
- •Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal medical therapy)
- •Chronic obstructive pulmonary disease (COPD) or any other disease concurrent with hypoxemia or oxygen saturation < 90% after a march of two minutes.
- •Current treatment with therapeutic doses of Coumadin (low dose Coumadin up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed).
- •Known human immunodeficiency virus infection.
- •Pregnancy or breastfeeding. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) prior to inclusion.
- •Previous allergic reaction to components structurally similar to TH-302 or sunitinib or any of the excipients of drugs.
- •Non-healing wound, fistulae, active peptic ulcer or bone fracture.
- •Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
研究组 & 干预措施
TH-302 + Sunitinib
Experimental
TH-302 + Sunitinib. Single arm Study.
干预措施: TH-302 + Sunitinib (Drug)
结局指标
主要结局
Objective Response Rate
时间窗: approximately 36 months
Objective response rate: percentage of patients in whom a complete response (CR) or a partial response (PR) is confirmed according Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria in relation to the total of the analyzed population. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions
次要结局
- Progression Free Survival (PFS)(approximately 36 months)
- Time to Tumour Progression (TTP)(approximately 36 months)
- Duration of Response (DR)(approximately 36 months)
- Overall Survival (OR)(approximately 36 months)
- Safety (Adverse Events)(time between the date of signing the informed consent until 28 days after the last dose of study drug, , an average of 2 years)
- Biomarkers in Serum and Tumor Tissue(approximately 36 months)
研究者
研究点 (10)
Loading locations...
相似试验
撤回
2 期
Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast CancerEstrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor NegativeRecurrent Breast CarcinomaTriple Negative Breast CancerMetastatic Breast CancerNCT03644589University of Washington
终止
2 期
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung CancerSmall Cell Lung CarcinomaNCT00299390Bayer10
招募中
1 期
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)Myelodysplastic SyndromesNCT03886662Lixte Biotechnology Holdings, Inc.47
进行中（未招募）
2 期
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract MalignanciesGastrointestinal Tract MalignanciesNCT05329766Arcus Biosciences, Inc.332
已完成
2 期
A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune SystemCOVID-19NCT05438602Pfizer157